Page last updated: 2024-09-05

dabigatran and Thrombocythemia, Essential

dabigatran has been researched along with Thrombocythemia, Essential in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A	1

Other Studies

1 other study(ies) available for dabigatran and Thrombocythemia, Essential

Article	Year
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study. Journal of cardiovascular pharmacology, 2021, 11-01, Volume: 78, Issue:5 Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism	2021

Article

Year

Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study.

Journal of cardiovascular pharmacology, 2021, 11-01, Volume: 78, Issue:5

Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism

2021